Table 3.

Conventionally fractionated stereotactic radiation therapy in recurrent  patients with glioblastoma

Author	Pts	Interval between RT courses	RT modality	Median dose/fractions	Imaging for planning	Median target volume (ml)	CTV/PTV margins (mm)	Systemic therapy	Median PFS (months)	Median OS (months)	EQD2 (Gy)	Cumulative EQD2 (Gy)	RN (%)
Combs et al., 2005 [74]	59	10	LINAC	36 Gy/18 fr	T1-w ce MRI	49.3 (2.5–636)	5–10 mm	TMZ, Carmustine, PCV, 36	5 (1–21)	8 23% at 1 year	36	96	0.6
Sholtyssek et al., 2013 [75]	53	13.4	LINAC	36 Gy/18 fr*	T1-w ce MRI	110.4. (1.8– 378)	CTV, 5 mm; PTV, 3–5 mm	TMZ,12; Carbo/etoposide, 24	4.3 33% at 6 m	7.7 24% at 1 year	36	96	0
Flieger et al., 2014 [76]	49	NR	LINAC	36 Gy/18 fr*	T1-w ce MRI	34.9 (1.95–157.9)	5–10 mm	CHT, 38; BEV,18	4.9	7.8	36	96	0
Wick et al., 2014 [77]	91	21	LINAC	36 Gy/18 fr	T1-w ce MRI	size > 2.5 cm in 35 pts	10 mm	SRT + APG101, 58 SRT, 21	2.5. 4.5(+ APG101)	SRT, 11.5; SRT + APG101, 11.5	36	96	1.2
Schnell et al., 2017 [78]	85	18.5	LINAC	36 Gy/18 fr	T1-w ce MRI	128	5–10 mm	Concomitant BEV, 33; Concomitant/ manteinance BEV, 25; BEV + IRI, 27	NR	concomitant BEV, 8; concomitant/ manteinance BEV, 13.1; BEV + IRI, 6.6	36	96	0
Shen et al., 2018 [79]	63	27.6	LINAC	41.4 Gy/23 fr	T1-w ce, DCE, DSC MRI	202 (20–901)	5–10 mm	TMZ, 35; BEV, 5; TMZ/BEV, 6	NR	6.7	41.4	101.4	3.4
Fleischmann et al., 2019 [30]	124	18	LINAC	36 Gy/18 fr*	T1-w ce MRI	118.1 (22.6–385.5)	CTV, 5 mm PTV, 3 mm	BEV, 95	5	9	36–48.4	96–108.4	6.9

LINAC, linear accelerator; CTV, clinical target volume; PTV, planning target volume; PFS, progression-free survival; OS, overall survival; EQD2, equivalent dose normalized to 2 Gy;

*Majorty of patients; SRT, stereotactic radiotherapy; T1-w ce MRI, T1-weighted contrast-enhanced magnetic resonance imaging; DCE, dynamic contrast enhanced; DSC, dynamic susceptibility;

BEV, bevacizumab; TMZ, temozolomide; IRI, irinotecan; Carbo, carboplatin